Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.78
(1.3%)
EUR 0.78
(1.3%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.29 Million EUR | 39.49% |
| 2022 | -3.78 Million EUR | 24.07% |
| 2021 | -4.98 Million EUR | -11616.48% |
| 2020 | -42.55 Thousand EUR | 94.5% |
| 2019 | -773.32 Thousand EUR | 42.25% |
| 2018 | -1.33 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -790.59 Thousand EUR | 65.49% |
| 2024 Q2 | -790.59 Thousand EUR | 0.0% |
| 2023 Q2 | -2.83 Million EUR | 2.16% |
| 2023 Q1 | -2.89 Million EUR | 23.51% |
| 2023 Q3 | -2.29 Million EUR | 19.15% |
| 2023 FY | -2.29 Million EUR | 39.49% |
| 2023 Q4 | -2.29 Million EUR | 0.0% |
| 2022 Q4 | -3.78 Million EUR | 0.0% |
| 2022 FY | -3.78 Million EUR | 24.07% |
| 2022 Q3 | -3.78 Million EUR | 12.92% |
| 2022 Q2 | -4.34 Million EUR | 1.9% |
| 2022 Q1 | -4.43 Million EUR | 11.11% |
| 2021 Q1 | -198.16 Thousand EUR | -365.4% |
| 2021 FY | -4.98 Million EUR | -11616.48% |
| 2021 Q4 | -4.98 Million EUR | 0.0% |
| 2021 Q2 | -198.16 Thousand EUR | 0.0% |
| 2021 Q3 | -4.98 Million EUR | -2416.36% |
| 2020 Q1 | 776.23 Thousand EUR | 0.0% |
| 2020 FY | -42.55 Thousand EUR | 94.5% |
| 2020 Q3 | -42.57 Thousand EUR | 0.0% |
| 2020 Q4 | -42.57 Thousand EUR | 0.0% |
| 2019 FY | -773.32 Thousand EUR | 42.25% |
| 2018 FY | -1.33 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | -2.73 Million EUR | 16.17% |
| Philogen S.p.A. | -720 Thousand EUR | -218.205% |